Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Retained Earnings: 2012-2025

Historic Retained Earnings for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$404.9 million.

  • Enanta Pharmaceuticals' Retained Earnings fell 25.35% to -$404.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$404.9 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of -$404.9 million for FY2025, which is 25.35% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Retained Earnings of -$404.9 million as of FY2025, which was down 25.35% from -$323.0 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Retained Earnings peaked at $48.6 million during FY2021, and registered a low of -$404.9 million during FY2025.
  • Its 3-year average for Retained Earnings is -$311.7 million, with a median of -$323.0 million in 2024.
  • Data for Enanta Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 250.65% (in 2022) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Retained Earnings (Yearly) stood at $48.6 million in 2021, then tumbled by 250.65% to -$73.2 million in 2022, then tumbled by 182.86% to -$207.0 million in 2023, then tumbled by 56.06% to -$323.0 million in 2024, then dropped by 25.35% to -$404.9 million in 2025.